Back to Search
Start Over
Genome-wide programmable transcriptional memory by CRISPR-based epigenome editing.
- Source :
-
Cell [Cell] 2021 Apr 29; Vol. 184 (9), pp. 2503-2519.e17. Date of Electronic Publication: 2021 Apr 09. - Publication Year :
- 2021
-
Abstract
- A general approach for heritably altering gene expression has the potential to enable many discovery and therapeutic efforts. Here, we present CRISPRoff-a programmable epigenetic memory writer consisting of a single dead Cas9 fusion protein that establishes DNA methylation and repressive histone modifications. Transient CRISPRoff expression initiates highly specific DNA methylation and gene repression that is maintained through cell division and differentiation of stem cells to neurons. Pairing CRISPRoff with genome-wide screens and analysis of chromatin marks establishes rules for heritable gene silencing. We identify single guide RNAs (sgRNAs) capable of silencing the large majority of genes including those lacking canonical CpG islands (CGIs) and reveal a wide targeting window extending beyond annotated CGIs. The broad ability of CRISPRoff to initiate heritable gene silencing even outside of CGIs expands the canonical model of methylation-based silencing and enables diverse applications including genome-wide screens, multiplexed cell engineering, enhancer silencing, and mechanistic exploration of epigenetic inheritance.<br />Competing Interests: Declaration of interests J.K.N., J.C., G.C.P., L.A.G., and J.S.W. have filed patent applications related to CRISPRoff, CRISPRon, and CRISPRi/a screening. J.M.R. consults for Maze Therapeutics. L.A.G., J.S.W., H.Y.C., and B.E.B. consult for and hold equity in Chroma Medicine. J.S.W. declares outside interest in KSQ Therapeutics, Maze Therapeutics, Amgen, and Tessera Therapeutics. M.K. serves on the Scientific Advisory Boards of Engine Biosciences, Casma Therapeutics, and Cajal Neuroscience. B.E.B. declares outside interests in Fulcrum Therapeutics, Arsenal Biosciences, HiFiBio, and Cell Signaling Technologies. H.Y.C. is a co-founder of Accent Therapeutics, Boundless Bio, and is an advisor for 10x Genomics, Arsenal Biosciences, and Spring Discovery.<br /> (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Subjects :
- Cell Differentiation
CpG Islands
DNA Methylation
Gene Silencing
Histone Code
Humans
Induced Pluripotent Stem Cells metabolism
Neurons metabolism
Protein Processing, Post-Translational
CRISPR-Cas Systems
Cellular Reprogramming
Epigenesis, Genetic
Epigenome
Gene Editing
Induced Pluripotent Stem Cells cytology
Neurons cytology
Subjects
Details
- Language :
- English
- ISSN :
- 1097-4172
- Volume :
- 184
- Issue :
- 9
- Database :
- MEDLINE
- Journal :
- Cell
- Publication Type :
- Academic Journal
- Accession number :
- 33838111
- Full Text :
- https://doi.org/10.1016/j.cell.2021.03.025